Therapeutic Progress Amid Political Turbulence: Could 2017 Be Pharma's Year?

Delivering clinical advances in areas including immuno-oncology and Alzheimer's disease data while navigating the stormy seas of global politics could represent an opportunity for pharma to influence change. An uptick in sector M&A could also ensue if Trump offers US corporations a tax holiday.

fishing boat giant wave storm rogue wave
• Source: Shutterstock

At the beginning of 2016, we expected the year in pharma to be dominated by immuno-oncology and M&A, with drug pricing questions, the US corporate taxation debate and fears about a bursting biotech bubble framing the picture.

Sure enough, immuno-oncology provided a constant stream of headlines throughout the year, and that won't change in 2017. Bristol-Myers...

More from Business

More from Scrip